Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 14/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17977039 | 0.85 | SMO (0.43) | SMOCYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL3174430 | 0.85 | SMO (0.55) | SMOOPRM1OPRL1CYP1A2CYP2C9 | |
| SCHEMBL3392057 | 0.82 | OPRM1 (0.40) | SMOOPRM1OPRL1CYP1A2CYP2C9 | |
| SCHEMBL14938608 | 0.81 | MAP4K4 (0.52) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL14938526 | 0.80 | HTR3A (0.53) | UHRF1CYP1A2KMT2A | |
| SCHEMBL29464176 | 0.80 | HTR3A (0.53) | UHRF1CYP1A2KMT2A | |
| SCHEMBL1100741 | 0.79 | UHRF1 (0.48) | UHRF1CYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL30298014 | 0.79 | UHRF1 (0.48) | OPRM1OPRL1UHRF1CYP1A2CYP2C9 | |
| SCHEMBL16178365 | 0.78 | ALDH1A1 (0.66) | SMOCYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL16178366 | 0.78 | ALDH1A1 (0.66) | SMOCYP1A2CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | SMO 2545/4885OPRM1 4282/4885OPRL1 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.